Columbia University Psychiatry Professors Prescribe Fisher Wallace Cranial Stimulator to Over 250 Patients Positive Patient Results Help Propel the Company's Drug-Free Treatment for Depression, Anxiety and Insomnia into the Mainstream
NEW YORK, Feb. 24 /PRNewswire/ -- Fisher Wallace Laboratories today announced that two psychiatry professors at Columbia University, Dr. Richard Brown and Dr. Andres San Martin, have prescribed the Fisher Wallace Cranial Stimulator to more than 250 patients suffering from depression, anxiety and insomnia. The handheld, FDA-sanctioned device generates micro-currents of electricity using patented radio frequencies that have been shown in several peer-reviewed studies to gently stimulate the brain's production of serotonin and dopamine (the neurochemicals required for psychological equilibrium and sound sleep).
Dr. Richard Brown is an associate clinical professor of psychiatry and Dr. Andres San Martin is an assistant clinical professor of psychiatry, both at Columbia University. Dr. Brown has consistently prescribed the device for over a year and Dr. San Martin has prescribed it for the past three months.
In addition to Dr. Brown and Dr. San Martin, currently more than sixty doctors have prescribed the Cranial Stimulator to thousands of patients.
Dr. Brown states, "I have seen very positive results, often within the first two weeks of using the device. Approximately 80 percent of my patients who have been diagnosed with generalized anxiety disorder, major depressive disorder, stress related disorders or insomnia have reported positive changes."
Dr. San Martin said, "I have had great success using the device to treat severe, chronic insomnia in patients who are resistant to pharmacotherapy. Also, patients who seek a drug-free alternative to treat insomnia have used the Cranial Stimulator to reduce or eliminate their dependence on prescription drugs."
"Knowing that two renowned psychiatrists have seen great results prescribing our Cranial Stimulator to more than 250 patients is an important milestone for Fisher Wallace," said Chip Fisher, president of Fisher Wallace Laboratories. "This number shows the confidence leading doctors have in drug-free alternatives and suggests the beginning of a tipping point for our device."
The Fisher Wallace Cranial Stimulator has been the subject of many peer-reviewed studies and pilot programs, all of which are documented on the company website. Most recently, the device was used in a successful pilot program with 399 patients at Phoenix House, the nation's largest, non-profit drug and alcohol rehabilitation center.
The devise can be purchased through the Fisher Wallace website for $695 and can be used at home without medical supervision. A prescription is required in the United States. Discounts are offered to members of the U.S. military for use in treating three of the most common symptoms of Post Traumatic Stress Disorder (PTSD): depression, anxiety and insomnia.
About Fisher Wallace Laboratories
Founded by Charles Avery Fisher, the son of stereo pioneer Avery Fisher, Fisher Wallace Laboratories manufactures the Fisher Wallace Cranial Stimulator, a cranial electrotherapy stimulation (CES) device sanctioned by the FDA for the treatment of depression, anxiety and insomnia. Today, Fisher Wallace Laboratories continues ground-breaking research at Harvard Medical School, Columbia Medical School, Massachusetts General Hospital, NYU Medical Center, University of Maryland, and the University of Medicine and Dentistry of New Jersey. The company's devices are made in the United States.
SOURCE Fisher Wallace Laboratories